AZ opens new global HQ in London
pharmafile | February 28, 2011 | News story | Medical Communications, Sales and Marketing | AZ, AstraZeneca, London
AstraZeneca has moved its London global headquarters from Mayfair to new, larger premises in Paddington.
The new offices are located in the Two Kingdom Street development in Paddington Central, and will be home to some 350 members of staff.
It will also accommodate around 90 staff from AstraZeneca’s global sales and marketing divisions, some of whom are relocating from the company’s US and Brussels operations.
The offices were officially opened by the Mayor of London Boris Johnson, who said the company had made a perfect choice of location in Paddington.
“This once derelict part of London has transformed itself into a thriving new business district providing quick access to the capital’s transport network, its airports and its centres of world class research.
“With Crossrail passing through Paddington in the near future, many more businesses will be heading west to reap the huge business benefits AstraZeneca has discovered in this fantastic corner of the capital.”
David Brennan, AstraZeneca chief executive, said: “We are really delighted that the Mayor of London, Boris Johnson, was able to celebrate with staff as we marked the opening of our new global headquarters.
“London is a world class city with a vibrant financial centre, with improving transport links and, being based in Paddington, we now have even better access to Heathrow Airport.”
In total AstraZeneca has 13 sites across the UK, employing 9,000 people and the Mayor’s office said the company supported a further 21,000 UK jobs.
But the AstraZeneca will be cutting back on R&D investment in the country, and plans to close its Charnwood facility in Loughborough with the loss of 1,200 jobs before the end of this year.
The company will also shutter research sites in the US and Sweden as it exits discovery research in 10 therapeutic categories, including depression, ovarian cancer and hepatitis C.
Dominic Tyer
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
